BRD4 Inhibitor PLX51107

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, Hannah Choe, MD

Conditions

Acute Graft Versus Host DiseaseAcute Myeloid LeukemiaMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative NeoplasmSteroid Refractory Graft Versus Host Disease

Phase 1

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

CompletedNCT04022785

M.D. Anderson Cancer CenterAcute Myeloid Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome +1

Start: 2019-09-09End: 2022-10-24Updated: 2022-10-31

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

TerminatedNCT04910152

Hannah Choe, MDAcute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease

Start: 2022-04-19End: 2023-09-28Updated: 2025-01-28

Related Papers

Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Blood2021-11-053 citations